Navigation Links
Immucor Announces Record Fiscal First Quarter Revenues

NORCROSS, Ga., Oct. 3 /PRNewswire-FirstCall/ -- Immucor, Inc. (Nasdaq: BLUD), a global leader in providing automated instrument-reagent systems to the blood transfusion industry, today reported financial results for the fiscal first quarter ended August 31, 2007.

Revenue for the fiscal first quarter was a record $63.6 million, up 25% from $51.0 million in the same period last year. Of the $12.6 million total increase in revenues, approximately $1.5 million came from volume increases including instrument, warranty and service revenue in the United States, approximately $8.7 million came from price increases in the United States, approximately $1.6 million came from sales increases including instrument revenues outside the United States, and the effect of the change in the Euro, Japanese Yen and Canadian dollar exchange rates increased sales by approximately $0.8 million. Gross margin improved during the quarter to 72.1% up from 67.7% in the prior year quarter.

Net income for the first quarter was $17.8 million, up 39% from $12.7 million for the same quarter last year. Diluted earnings per share totaled $0.25 on 71.1 million weighted average shares outstanding, up from $0.18 on 70.2 million weighted average shares outstanding for the same period last year.

Sales of instruments were $5.1 million in the first quarter of fiscal 2008, an increase from $3.3 million in the fiscal 2007 first quarter. Most instrument sales in the United States are recognized over the life of the underlying reagent contract, which is usually 5 years. In the quarter ended August 31, 2007 approximately $2.9 million of instrument sales were deferred in this manner. As of August 31, 2007, deferred instrument revenues, including deferred service revenues, totaled $21.4 million. Reagent gross margin grew to 80.6% during the first quarter of fiscal 2008 compared to 75.3% in the same period last year. The previously mentioned price increases were responsible for this improvement.

"We are pleased with our quarterly results," said Dr. Gioacchino De Chirico, President and Chief Executive Officer. "Revenues and net income were both records for a fiscal first quarter, and revenues were also a record for any fiscal quarter. Our strategies to grow our business and the execution of our plan continue to generate outstanding results in terms of revenues, margins and net income." Commenting further, Dr. De Chirico stated, "Based on the very positive customer reaction to the launch of the Galileo ECHO(TM) in the United States and Europe we believe we can achieve future market share gains and revenue growth through continued Galileo(R) placements and now placements of the Galileo ECHO(TM). We previously announced that the Company has commenced research and development work on a second generation Galileo and we expect that improvements in the second generation Galileo will extend by several years the life of the instrument in the market. As of August 31, 2007, the Company had received purchase orders for a total of 504 Galileo instruments worldwide (an increase of 23 in the quarter), including 292 in Europe, 210 in North America and 2 in Japan, and 456 of these instruments were generating reagent revenues, an increase of 33 in the quarter. As of August 31, 2007, the Company had received purchase orders for a total of 30 Echo instruments worldwide."

Selected Highlights

-Sales of traditional reagent products, i.e., products not using the Company's patented Capture(R) technology, increased $7.6 million, or 20%, from $37.5 million in the first quarter of 2007 to $45.1 million in the first quarter of 2008. Sales of Capture products increased approximately $2.7 million to $11.9 million, a 30% increase over the prior year quarter.

-The gross margin on traditional reagents was 79.6% for the current quarter, compared with 74.2% in the prior year quarter. The increase in gross margin is primarily due to price increases in the United States. The gross margin on Capture(R) products was 84.6% for the current quarter, compared with 79.8% in the prior year quarter. Sales of instruments were $5.1 million in the first quarter of 2008 compared to $3.3 million in the first quarter of 2007. The gross margin on instruments, including the impact of the cost of providing service, was a negative 4.1% for the current quarter, compared to a negative 31.2% for the same quarter last year.

-The effect on revenues of the change in the Euro, Japanese Yen and Canadian dollar exchange rates was an increase of approximately $0.8 million for the first quarter of fiscal 2008 as compared to the prior year quarter. The effect on net income of the change in the Euro, Japanese Yen and Canadian dollar exchange rates was an increase of approximately $0.1 million in the quarter ended August 31, 2007 as compared to the prior year quarter.

-Distribution expenses increased by $0.4 million in the first quarter and selling and marketing expenses increased by $2.0 million as compared to the prior year quarter. Selling and marketing expenses in the United States were impacted by an increase of $0.5 million in personnel costs, an increase in travel costs of $0.2 million, an increase in sales meeting and convention costs associated with the Echo launch of $0.3 million, and an increase in commission expense of $0.2 million General and administrative expenses increased by $0.7 million for the first quarter of fiscal 2008 as compared to the prior year quarter. General and administrative expenses were impacted by a $0.3 million increase in personnel costs, a $0.8 million increase in management bonus and stock based compensation expense, a $0.3 million increase in tax services, and a $0.3 million increase in FICA expense associated with employee stock option exercises, partially offset by a $1.0 million decrease in audit and SOX costs. Research and development expenses increased by $0.8 million to $2.1 million in the first quarter caused by a $0.6 million in costs associated with the work on the second generation Galileo, and an increase in personnel costs of $0.1 million. Restructuring costs related to the Houston closure were $0.5 million in the first quarter an increase of $0.1 million compared to the prior year quarter.

-Human collagen sales increased approximately $0.4 million to $1.5 million. We plan to discontinue the production of collagen in calendar 2007 when our present commitment to a third party expires. The gross margin on human collagen sales was 8.4% during the quarter, compared with 37.5% in the prior year quarter.

-Operations continue to generate strong cash flow. Cash, cash equivalents and marketable securities totaled $124.8 million at the end of the current quarter compared to $113.6 million at May 31, 2007.

Immucor, Inc. will host a conference call October 4, 2007 at 8:30 a.m. (EDT) to review these results. Investors are invited to participate in this conference call with Dr. Gioacchino De Chirico, President and Chief Executive Officer; Patrick Waddy, Chief Financial Officer, and Edward L. Gallup, consultant. The call will focus on the results for the first quarter and general business trends. This earnings release will be posted on Immucor's website, as well as any material financial information that may be discussed by Messrs. De Chirico, Waddy or Gallup during this call that is not contained in the earnings release. Both this earnings release and the additional financial information, if any, will be posted as soon as practicable after the call on the investor news section of Immucor's website. To access this information once posted, go to Immucor's website at and click on "About Us - Press Releases." To participate in the telephone conference call, dial 1-800-593-0187, pass code BLUD. Replays of the conference call will be available for one week beginning at 12:00 PM on October 04, 2007 by calling 1-888-484-8256. Beginning October 11, 2007, audio of the conference call or a transcript of the audio will be available on the "About Us - Press Releases" page of the Immucor website.

Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used by hospitals, reference laboratories and donor centers to detect and identify certain properties of the cell and serum components of blood prior to transfusion. Immucor markets a complete family of automated instrumentation for all of its market segments.

For more information on Immucor, please visit our website at

Statements contained in this press release that are not statements of historical fact are "forward-looking statements" as that term is defined under federal securities laws, including, without limitation, all statements concerning Immucor's expectations, beliefs, intentions or strategies for the future. Forward-looking statements may be identified by words such as "plans," "expects," "believes," "anticipates," "estimates," "projects," "will," "should" and other words of similar meaning used in conjunction with, among other things, discussions of future operations, financial performance, product development and new product launches, FDA and other regulatory applications and approvals, market position and expenditures. Factors that could cause actual results to differ materially from those expressed in any forward-looking statement include the following: lower than expected market acceptance of our new Galileo Echo instrument; the decision of customers to defer capital spending; the inability of customers to efficiently integrate our instruments into their blood banking operations; increased competition in the sale of instruments and reagents, particularly in North America; product development or regulatory obstacles; the ability to hire and retain key managers; changes in interest rates; fluctuations in foreign currency conversion rates; the ability of the Company's Japanese subsidiary to attain expected revenue, gross margin and net income levels; the outcome of any legal claims known or unknown; delays in regulatory approvals required to move Houston manufacturing to another Company facility; other currently unforeseen events that could delay the move; higher than expected Houston closure costs; higher than expected manufacturing consolidation costs; the unexpected application of different accounting rules; and general economic conditions. Further risks are detailed in the Company's filings with the Securities and Exchange Commission. Investors are cautioned not to place undue reliance on any forward-looking statements. Immucor assumes no obligation to update any forward-looking statements.



(Amounts in thousands except per share data)


Three Months Ended

August 31, August 31,

2007 2006

NET SALES $63,632 $51,040

COST OF SALES 17,751 16,504

GROSS PROFIT 45,881 34,536


Research and development 2,055 1,226

Selling and marketing 7,569 5,559

Distribution 2,684 2,288

General and administrative 5,880 5,222

Restructuring expense 531 387

Amortization expense and other 86 87

Total operating expenses 18,805 14,769



Interest income 1,113 518

Interest expense (95) (117)

Other, net (182) (61)

Total non-operating income 836 340



NET INCOME $17,750 $12,733

Earnings per share:

Per common share - basic $0.26 $0.19

Per common share - assuming dilution $0.25 $0.18


Selected Condensed Consolidated

Balance Sheet Items

(Amounts in thousands)

August 31, 2007 May 31, 2007


Cash $124,778 $113,551

Accounts receivable - trade 50,309 47,768

Inventory 34,578 29,320

Total current assets 219,375 199,820

Property and equipment - net 32,024 30,245

Total assets 299,926 275,478

Accounts payable 7,640 8,056

Total current liabilities 44,530 36,955

Other liabilities 15,774 19,075

Shareholders' equity 239,622 219,448

SOURCE Immucor, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
(Date:10/13/2017)... , ... October 13, 2017 , ... As health professionals ... known as “patient engagement.” The patient is doing more than filling out a survey; ... , “There is an increasing emphasis in health care and research on the importance ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Pharmacy (SOP) alumni Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, ... guideline updates for the primary prevention of cardiovascular diseases during the 15th ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network for ... for action towards gender equality at their inaugural Summit in New York City in ... reached a social audience of over 3 million. To watch the Mobilize Women video, ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the ... danger possible to save lost souls in the Philippines. “The Journey: From the Mountains ... a dedicated teacher of the Bible. She has taught all ages and currently teaches ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  BioPharmX Corporation (NYSE ... team that developed an innovative way to use nonlinear ... the delivery of new drugs. ... Clinical Dermatology Conference will show how researchers from BioPharmX ... Harvard Medical School used a suite of imaging techniques ...
(Date:10/10/2017)... Oct. 10, 2017  NDS received FDA 510(k) clearance in May ... battery-powered display stand specifically designed for endoscopy environments. An innovative secondary ... a clinical solution to support the improvement of patient outcomes, procedural ... ... ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
Breaking Medicine Technology: